



SHL/SEC/2024

November 13, 2024

**The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street,
Fort
Mumbai – 400 001.**

**The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India**

Company Code: **537253**

Dear Sir,

Sub. : **Outcome of the 261st Board Meeting held on 13.11.2024**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, that the Board of Directors of the Company at their Board Meeting held on Wednesday, November 13, 2024 interalia approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2024 of the FY 2024-25.

Copy of the approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2024 of the FY 2024-25 alongwith the Limited Review report thereon are enclosed herewith.

The Board meeting was started at 4:40 p.m. and concluded at 6:45 p.m.

You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,
for **Sunil Healthcare Limited**

Satyendu Pattnaik
Company Secretary & Compliance Officer
FCS-7736
Encl a/a

Sunil Healthcare Ltd.

38E/252-A, Vijay Tower, Opp Panchsheel Park Comm. Complex, New Delhi -110049

T: +91 -11-49435555/00, F: +91 -11-43850087 Email : info@sunilhealthcare.com, Web: www.sunilhealthcare.com

CIN No. : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2024

Rs. in Lakhs

Particulars	Standalone					Year Ended Standalone	Consolidated					Year Ended Consolidated
	Quarter ended		Half Year Ended				Quarter ended		Half Year Ended			
	30th September 2024	30th June 2024	30th September 2023	30th September 2024	30th September 2023	31st March 2024	30th September 2024	30th June 2024	30th September 2023	30th September 2024	30th September 2023	31st March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	2,025.77	2,149.55	2,357.65	4,175.32	4,570.88	8,968.75	2,025.77	2,149.55	2,370.16	4,175.32	4,621.11	9,019.19
2 Other Income	19.33	10.39	33.14	29.72	114.74	469.63	17.65	14.14	21.97	31.79	140.78	522.05
3 Total Income (1+2)	2,045.10	2,159.94	2,390.79	4,205.04	4,685.62	9,438.38	2,043.42	2,163.69	2,392.13	4,207.11	4,761.89	9,541.24
4 Expenses												
a) Cost of Materials consumed	946.69	921.24	1,229.73	1,867.93	2,452.91	4,690.24	946.69	921.24	1,229.73	1,867.93	2,452.91	4,690.24
b) Purchase of Stock-in-trade	4.65	6.05	0.94	10.70	0.94	7.77	4.65	6.05	0.94	10.70	0.94	7.66
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(64.14)	91.08	(18.91)	26.94	(108.87)	(64.36)	(62.52)	90.27	(27.40)	27.75	(100.33)	(59.78)
d) Employees benefit expenses	285.23	290.54	333.81	575.77	658.26	1,293.86	285.23	290.54	333.81	575.77	658.26	1,293.86
e) Finance Costs	149.97	151.46	131.25	301.43	257.89	577.75	149.97	151.46	131.25	301.43	257.89	577.75
f) Depreciation and amortisation expense	150.60	148.43	159.26	299.03	320.04	608.34	150.62	148.48	159.31	299.10	320.14	608.55
g) Other Expenses	565.35	545.50	693.27	1,110.85	1,341.61	2,612.82	620.10	620.33	710.62	1,240.43	1,405.10	2,678.47
Total Expenses	2,038.35	2,154.30	2,529.35	4,192.65	4,922.78	9,726.42	2,094.74	2,228.37	2,538.26	4,323.11	4,994.91	9,796.75
5 Profit before tax (3-4)	6.75	5.64	(138.56)	12.39	(237.16)	(288.04)	(51.32)	(64.68)	(146.13)	(116.00)	(233.02)	(255.51)
6 Tax Expenses (Net)	3.51	4.45	(36.55)	7.96	(59.54)	(77.26)	3.51	4.45	(36.24)	7.96	(58.96)	(76.66)
a) Current Tax	-	-	-	5.76	-	-	5.76	-	0.31	5.76	0.58	0.59
i)-Current Tax	5.76	-	-	-	-	-	-	-	-	-	-	9.30
ii)-Tax for Earlier Period	-	-	-	-	-	9.30	-	-	-	-	-	-
b) Deferred Tax Charged/(Credit)	(2.25)	4.45	(36.55)	2.20	(59.54)	(86.56)	(2.25)	4.45	(36.55)	2.20	(59.54)	(86.55)
7 Profit/(loss) after tax	3.24	1.19	(102.01)	4.43	(177.62)	(210.78)	(54.83)	(69.13)	(109.89)	(123.96)	(174.06)	(178.85)
8 Other Comprehensive Income (OCI)	(12.72)	(12.72)	-	(25.44)	-	1,442.61	22.45	30.07	2.29	52.52	(17.97)	1,400.84
a) Items that will not be reclassified to Profit or Loss (net of tax)	(12.72)	(12.72)	-	(25.44)	-	1,442.61	(12.72)	(12.72)	-	(25.44)	-	1,442.61
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	35.17	42.79	2.29	77.96	(17.97)	(41.77)
9 Total Comprehensive Income	(9.48)	(11.53)	(102.01)	(21.01)	(177.62)	1,231.83	(32.38)	(39.06)	(107.60)	(71.44)	(192.03)	1,221.99
10 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11 Other Equity						6,378.90						5,796.20
12 Earning per share of Rs.10/- each(not annualised)												
(a) Basic (Rs.)	0.03	0.01	(0.99)	0.04	(1.73)	(2.06)	(0.53)	(0.67)	(1.07)	(1.21)	(1.70)	(1.74)
(b) Diluted (Rs.)	0.03	0.01	(0.99)	0.04	(1.73)	(2.06)	(0.53)	(0.67)	(1.07)	(1.21)	(1.70)	(1.74)



Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	As at 30th September 2024	As at 31st March 2024	As at 30th September 2023	As at 31st March 2024
	Un-audited	Audited	Un-audited	Audited
A ASSETS				
1 Non Current Assets				
(a) Fixed Assets				
(i) Property, Plant and Equipment	6,298.72	5,430.12	6,298.72	5,430.19
(ii) Capital Work-in-Progress	1.84	565.69	1.84	565.69
(iii) Right of Use Assets	3,244.31	3,277.47	3,244.31	3,277.47
(iv) Other Intangible Assets	5.93	8.02	5.93	8.02
(b) Financial Assets				
(i) Investment	0.10	0.10	-	-
(ii) Other financial assets	123.75	211.74	125.08	213.32
(c) Other non-current Assets	81.26	106.64	81.26	106.64
2 Current Assets				
(a) Inventories	1,367.30	1,266.60	1,462.29	1,405.42
(b) Financial Assets				
(i) Trade Receivables	4,784.09	4,726.93	4,112.50	4,058.67
(ii) Cash and Cash Equivalents	18.84	5.36	20.90	7.89
(iii) Other Bank Balances	279.02	353.18	279.02	353.18
(iv) Loan	50.42	50.02	-	-
(v) Other Financial Assets	70.69	51.66	35.63	19.61
(c) Current Tax Assets	9.65	18.75	9.65	18.75
(d) Other Current Assets	151.19	316.91	208.97	385.14
TOTAL ASSETS	16,487.11	16,389.19	15,886.10	15,849.99
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
(b) Other Equity	6,357.89	6,378.90	5,724.76	5,796.20
2 Non Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,142.53	2,026.08	2,142.53	2,026.08
(b) Provisions	145.47	129.67	145.47	129.67
(c) Deferred Tax Liabilities (Net)	1,136.97	1,142.49	1,136.97	1,142.50
3 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,020.30	4,589.03	4,020.30	4,589.03
(ii) Trade Payables				
Total Outstanding dues of Micro enterprises and small enterprises ; and	388.99	213.78	388.99	213.78
Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	722.23	362.51	752.52	394.34
(iii) Other Financial Liabilities	242.24	306.92	242.24	306.92
(b) Other Current Liabilities	205.68	115.00	207.51	121.11
(c) Current tax liabilities(Net)	-	-	-	5.55
(d) Provisions	99.33	99.33	99.33	99.33
TOTAL - EQUITY AND LIABILITIES	16,487.11	16,389.19	15,886.10	15,849.99



Cash Flow Statement

3	Particulars	Standalone		Consolidated	
		For the Half year ended	For the Half year ended	For the Half year ended	For the Half year ended
		30th Sep 2024	30th Sep 2023	30th Sep 2024	30th Sep 2023
	Un-audited	Un-audited	Un-audited	Un-audited	
A. Cash Flow From Operating Activities					
Profit/(loss) before Tax	12.39	(237.16)	(116.00)	(233.02)	
Adjustment for :					
Finance Costs	301.43	257.89	301.43	257.89	
Depreciation and Amortization Expenses	299.03	320.04	299.10	320.14	
Sundry balances written off	-	8.98	-	8.98	
Net (Profit)/Loss on sales/discard of Property ,Plant and Equipment	0.10	0.01	0.10	0.01	
Provision for Expected Credit Loss	20.56	-	20.56	-	
Interest Income	(14.52)	(10.56)	(11.50)	(10.56)	
Gain on Lease Modification	-	(10.06)	-	(10.06)	
Unspent liabilities written back	-	(51.41)	-	(51.41)	
Unrealised (gain)/loss foreign currency transactions and translation	(28.51)	(20.64)	49.45	(38.61)	
Operating profit before working capital changes	590.48	257.09	543.14	243.36	
Changes in working Capital:					
(Increase)/Decrease in Inventories	(100.70)	(345.88)	(56.87)	(350.70)	
(Increase)/Decrease in Trade and other Receivables	87.19	(959.70)	94.23	(1,001.89)	
Increase /(Decrease) in Trade and other payable	621.62	129.45	617.62	134.69	
Cash generation from Operation	1,198.59	(919.04)	1,198.12	(974.54)	
(Payment)/refund of Direct Taxes	3.34	0.42	3.34	0.63	
Net Cash generated from/ (used in) Operating Activities	1,201.93	(918.62)	1,201.46	(973.91)	
B. Cash Flow from Investing Activities					
Purchase of Property, Plant and Equipment & Intangible Assets including Capital work-in-prog	(579.54)	(91.71)	(579.54)	(91.71)	
Movement in Term Deposits	152.41	-	152.41	-	
Interest Received	5.21	3.23	5.21	3.23	
Net Cash generated from/ (used in) Investing Activities	(421.92)	(88.48)	(421.92)	(88.48)	
C. Cash Flow from Financing Activities					
Receipts from Non Current Borrowings	444.37	250.00	444.37	250.00	
Repayment of Non Current Borrowings	(284.19)	836.60	(284.19)	836.60	
Loan repaid to a Director	(3.00)	(66.50)	(3.00)	(66.50)	
Receipts/(Repayment) of Current Borrowings (Net)	(611.79)	234.24	(611.79)	234.24	
Payment of lease liability	-	(12.89)	-	(12.89)	
Finance Costs Paid	(311.92)	(234.16)	(311.92)	(234.16)	
Net Cash generated from/ (used in) Financing Activities	(766.53)	1,007.29	(766.53)	1,007.29	
Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	13.48	0.19	13.01	(55.10)	
Add : Opening Cash and Cash Equivalents	5.36	1.58	7.89	58.67	
Closing Cash and Cash Equivalents	18.84	1.77	20.90	3.57	

4 These financials results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) prescribed u/s 133 of the companies act, 2013 and other recognised accounting practises and policies to the extent applicable.

5 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

6 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 13, 2024 .

Place: NEW DELHI

Date: 13-11-2024



Harish Pal Kumar
Independent Director
DIN-01826010

Independent Auditor's Review Report on standalone unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2024. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E



Bimal Kumar Sipani
Partner

Membership No. 088926

UDIN:24088926BKEMKT1148

Place: Noida (Delhi-NCR)

Date: November 13, 2024

Independent Auditor's Review Report on consolidated unaudited quarterly and half yearly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2024, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total assets of Rs. 425.05 Lakhs as at September 30, 2024 and total revenue from operation of Nil and Nil, and loss after tax of Rs. 56.71 Lakhs and Rs. 127.84 Lakhs and total comprehensive income of (Rs. 21.28 Lakhs) and (Rs. 49.62 Lakhs) for the quarter and half year ended September 30, 2024 respectively, and net cash outflow of Rs. 0.47 Lakhs for the half year ended September 30, 2024 as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Singhi & Co.

Chartered Accountants

Firm Registration No. 302049E



Bimal Kumar Sipani

Partner

Membership No. 088926

UDIN: 24088926BKEMKU9098

Place: Noida (Delhi-NCR)

Date: November 13, 2024